1. Home
  2. IHRT vs RLMD Comparison

IHRT vs RLMD Comparison

Compare IHRT & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo iHeartMedia Inc.

IHRT

iHeartMedia Inc.

SELL

Current Price

$1.80

Market Cap

300.3M

ML Signal

SELL

Logo Relmada Therapeutics Inc.

RLMD

Relmada Therapeutics Inc.

HOLD

Current Price

$3.25

Market Cap

348.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IHRT
RLMD
Founded
1974
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Broadcasting
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
300.3M
348.8M
IPO Year
2019
2012

Fundamental Metrics

Financial Performance
Metric
IHRT
RLMD
Price
$1.80
$3.25
Analyst Decision
Sell
Strong Buy
Analyst Count
4
4
Target Price
$3.63
★ $10.75
AVG Volume (30 Days)
637.3K
★ 1.4M
Earning Date
11-09-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 54.19
45.28
EPS
N/A
★ N/A
Revenue
★ $3,864,991,000.00
$13,070.00
Revenue This Year
$7.20
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
0.27
★ 154.83
52 Week Low
$1.38
$2.15
52 Week High
$6.56
$8.00

Technical Indicators

Market Signals
Indicator
IHRT
RLMD
Relative Strength Index (RSI) 41.82 38.09
Support Level N/A $3.13
Resistance Level $2.90 $3.55
Average True Range (ATR) 0.14 0.20
MACD 0.03 0.04
Stochastic Oscillator 66.67 32.28

Price Performance

Historical Comparison
IHRT
RLMD

About IHRT iHeartMedia Inc.

iHeartMedia Inc is a United States-based audio media company. The company operates through the segments of the Multiplatform Group, the Digital Audio Group, and the Audio & Media Services Group. The company derives prime revenue from the Multiplatform Group segment which includes the company's Broadcast radio, Networks and Sponsorships, and Events businesses. The Digital Audio Group segment includes all of the company's digital businesses, including podcasting; and the Audio & Media Services Group includes Katz Media Group, a full-service media representation business, and RCS Sound Software, a provider of scheduling and broadcast software and services.

About RLMD Relmada Therapeutics Inc.

Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.

Share on Social Networks: